Welcome Treatment Range


Treatment tolerance of particle therapy in pediatric patients.
Rieber JG, Kessel KA, Witt O, Behnisch W, Kulozik AE, Debus J, Combs SE.
Acta Oncol. 2015 Jan 23:1-7. PMID:25615893


Radiosensitization by histone deacetylase inhibition in an osteosarcoma mouse model.
Blattmann C, Thiemann M, Stenzinger A, Christmann A, Roth E, Ehemann V, Debus J, Kulozik AE, Weichert W, Huber PE, Oertel S, Abdollahi A.Strahlenther Onkol. 2013 Nov;189(11):957-66. doi: 10.1007/s00066-013-0372-8. Epub 2013 Jun 27. PMID: 23801068


Treatment of pediatric patients and young adults with particle therapy at the Heidelberg Ion Therapy Center (HIT): establishment of workflow and initial clinical data.
Combs SE, Kessel KA, Herfarth K, Jensen A, Oertel S, Blattmann C, Ecker S, Hoess A, Martin E, Witt O, Jäkel O, Kulozik AE, Debus J.
Radiat Oncol. 2012 Oct 17;7:170. doi: 10.1186/1748-717X-7-170


Suberoylanilide hydroxamic acid affects γH2AX expression in osteosarcoma, atypical teratoid rhabdoid tumor and normal tissue cell lines after irradiation.
Blattmann C, Oertel S, Thiemann M, Weber KJ, Schmezer P, Zelezny O, Lopez Perez R, Kulozik AE, Debus J, Ehemann V.
Strahlenther Onkol. 2012 Feb;188(2):168-76. doi: 10.1007/s00066-011-0028-5. Epub 2012 Jan 18


Combination of suberoylanilide hydroxamic acid with heavy ion therapy shows promising effects in infantile sarcoma cell lines.
Oertel S, Thiemann M, Richter K, Weber KJ, Huber PE, Perez RL, Brons S, Bischof M, Kulozik AE, Ehemann V, Debus J, Blattmann C.
Radiat Oncol. 2011 Sep 20;6:119. doi: 10.1186/1748-717X-6-119


Heidelberg Ion Therapy Center (HIT): Initial clinical experience in the first 80 patients.
Combs SE, Ellerbrock M, Haberer T, Habermehl D, Hoess A, Jäkel O, Jensen A, Klemm S, Münter M, Naumann J, Nikoghosyan A, Oertel S, Parodi K, Rieken S, Debus J.
Acta Oncol. 2010 Oct;49(7):1132-40.


Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma.
Blattmann C, Oertel S, Schulz-Ertner D, Rieken S, Haufe S, Ewerbeck V, Unterberg A, Karapanagiotou-Schenkel I, Combs SE, Nikoghosyan A, Bischof M, Jäkel O, Huber P, Kulozik AE, Debus J.BMC Cancer. 2010 Mar 12;10:96. doi: 10.1186/1471-2407-10-96


Long-term outcome after polychemotherapy and intensive local radiotherapy of high-gradeosteosarcoma.
Hundsdoerfer P, Albrecht M, Rühl U, Fengler R, Kulozik AE, Henze G.
Eur J Cancer 2009;11-2447-51.